[1] Doherty TJ. Invited review: Aging and sarcopenia. J Appl Physiol (1985),2003,95:1717-27.
[2] Ebadi M, Bhanji RA, Mazurak VC, et al. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol,2019,54:845-859.
[3] Kim G, Kang SH, Kim MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS One,2017,12:e0186990.
[4] Tantai X, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol,2022,76:588-599.
[5] Ebadi M, Burra P, Zanetto A, et al. Current treatment strategies and future possibilities for sarcopenia in cirrhosis. J Hepatol,2023,78:889-892.
[6] Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2021,74:1611-1644.
[7] Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology,2008,48:557-566.
[8] Ismaiel A, Bucsa C, Farcas A, et al. Effects of Branched-Chain Amino Acids on Parameters Evaluating Sarcopenia in Liver Cirrhosis: Systematic Review and Meta-Analysis. Front Nutr, 2022,9:749969.
[9] Konstantis G, Pourzitaki C, Chourdakis M, et al. Efficacy of branched chain amino acids supplementation in liver cirrhosis: A systematic review and meta-analysis. Clin Nutr 2022;41:1171-1190.
[10] Tsien C, Davuluri G, Singh D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology,2015,61:2018-2029.
[11] Lattanzi B, Bruni A, Di Cola S, et al. The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study. Nutrients,2021,13(7):2296.
[12] Hiraoka A, Michitaka K, Kiguchi D, et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. Eur J Gastroenterol Hepatol,2017,29:1416-1423.
[13] Kitajima Y, Takahashi H, Akiyama T, et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis. J Gastroenterol,2018,53:427-437.
[14] Uojima H, Sakurai S, Hidaka H, et al. Effect of branched-chain amino acid supplements on muscle strength and muscle mass in patients with liver cirrhosis. Eur J Gastroenterol Hepatol,2017,29:1402-1407.
[15] Kumar A, Davuluri G, Silva RNE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology,2017,65:2045-2058.
[16] Murata K, Kaji K, Nishimura N, et al. Rifaximin enhances the L?carnitine?mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut liver muscle axis. Int J Mol Med,2022,50(2):101.
[17] Hiramatsu A, Aikata H, Uchikawa S, et al. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. Hepatol Commun, 2019,3:348-355.
[18] Ohashi K, Ishikawa T, Hoshii A, et al. Effect of levocarnitine administration in patients with chronic liver disease. Exp Ther Med,2020,20:94.
[19] Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab,2008,33:997-1006.
[20] Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. J Hepatol, 2016,65:906-913.
[21] Saeki C, Kanai T, Nakano M, et al. Low Serum Branched-Chain Amino Acid and Insulin-Like Growth Factor-1 Levels Are Associated with Sarcopenia and Slow Gait Speed in Patients with Liver Cirrhosis. J Clin Med,2020,9(10):3239.
[22] Conchillo M, de Knegt RJ, Payeras M, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol,2005,43:630-636.
[23] Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest,2005,128:1187-1193.
[24] Feike Y, Zhijie L, Wei C. Advances in research on pharmacotherapy of sarcopenia. Aging Med (Milton),2021,4:221-233.
[25] Tsien C, Shah SN, McCullough AJ, et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol,2013,25:85-93.
[26] Gioia S, Merli M, Nardelli S, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver Int,2019,39:871-877.
[27] Hirooka M, Koizumi Y, Tanaka T, et al. Treatment on the Spleen Prevents the Progression of Secondary Sarcopenia in Patients With Liver Cirrhosis. Hepatol Commun, 2020,4:1812-1823.
[28] Ebadi M, Bhanji RA, Dunichand-Hoedl AR, et al. Sarcopenia Severity Based on Computed Tomography Image Analysis in Patients with Cirrhosis. Nutrients,2020,12(11):3463. |
